PRODUCT

Introduction to Boryung
caring for people’s health

Main Products

A guide to Boryung’ main
products.

Products

A guide to all
Boryung’s products.

close

R&D

The Boryung Company,
envisioning a world with a
healthy mankind.

R&D Vision·Strategy

Boryung’ goal is to develop
into a global company.

Pipeline

The research team at Boryung
aims to lead the future of the
pharmaceutical industry.

close

GLOBAL
BUSINESS

An introduction of
Boryung’ global business.

Introduction

The best global company.

CMO

Introducing BRCMO business

Network

50 markets and 150 partners worldwide.

close

PR

An introduction of Boryung ’ value -
Envisioning a healthy mankind.

Advertising

An introduction of video
and printed advertisements of Boryung.

close

Directions

An introduction of Boryung
Pharmaceutical’ value - Envisioning
a healthy mankind.

Directions

An introduction of video
and printed advertisements of Boryung.

close

Pipeline

The Research Team at Boryung aims to lead the Future of the Pharmaceutical Industry

  • Pipeline Introduction

    After 12 years of research, Boryung succeeded in developing the first domestic hypertension drug, ‘Kanarb’. By independently carrying out all the necessary steps – candidate material excavation, raw material synthesis, formulation research, a non-clinical trial, and clinical trial phases one, two and three – Boryung has established our very own capability for drug development. Boryung was established based on its drug development capabilities. We are expanding our scope of research into a variety of areas to develop drugs for cancer treatment, antibiotics, NCE(New Chemical Entity) and gene therapy that focuses on cardiovascular and other major diseases, vaccines and other biopharmaceuticals. We are particularly focused on the development of the Kanarb Value-Up Pipeline. In addition, we are focusing on the research and development of new API(Active Pharmaceutical Ingredient) products aimed at the globalization of API.

Kanarb Value-up Pipeline

The ‘Kanarb Value-up Pipeline’ consists of products that allow for the integrative treatment of patients with hypertension associated with the majority of metabolic diseases. These products are all NCE and IMDs and developed in-house.
Development of the ‘Kanarb Value-up Pipeline’ will not only increase sales in the single and composite drug market, but will also strengthen the global competitiveness of Kanarb through the global license out.

(Jan. 2022 standard)

Kanarb Value-up Pipeline
Classification Project Name Treatment for Discovery Pre-clinical Phase 1 Phase 2 Phase 3
IMD BR1010 Hypertension
BR1015 Hypertension

Kanarb Value-up Pipeline

(Jan. 2022 standard)

Kanarb Value-up Pipeline
IMD

BR1010

Hypertension

Discovery Pre-
clinical
Phase 1 Phase 2 Phase 3
Kanarb Value-up Pipeline
IMD

BR1015

Hypertension

Discovery Pre-
clinical
Phase 1 Phase 2 Phase 3

Pipeline

We are strengthening our R&D portfolio to focus on antibiotics and major diseases such as cancer and cardiovascular disease (CV). We will add a new pipeline that centers on diseases whose markets are expected to grow in the future. We are also focusing on developing NCE and incrementally modified drugs (IMD) to fulfill unmet needs, while working to discover new drugs on the cutting edge of bio-tech.

(Jan. 2022 standard)

Main Pipeline
Classification Project Name Treatment for Discovery Pre-clinical Phase 1 Phase 2 Phase 3
NCE BR2002 Cancer
BR2010 Cancer
BR2011 Cancer
NBE VT-EBV-201 Cancer
NCE
(external)
Lurbinectedin Cancer
Plitidepsin Cancer
PeproStat Haemostasis
ReadyFlow Haemostasis
IMD BR4002 Alzheheimer's disease
BR9003 Smoking cessation treatment
BR3003 Diabetes

Pipeline

(Jan. 2022 standard)

Main Pipeline
NCE

BR2002

Cancer

Discovery Pre-
clinical
Phase 1 Phase 2 Phase 3

BR2010

Cancer

Discovery Pre-
clinical
Phase 1 Phase 2 Phase 3

BR2011

Cancer

Discovery Pre-
clinical
Phase 1 Phase 2 Phase 3
NBE

VT-EBV-201

Cancer

Discovery Pre-
clinical
Phase 1 Phase 2 Phase 3
NCE(external)

Lurbinectedin

Cancer

Discovery Pre-
clinical
Phase 1 Phase 2 Phase 3

Plitidepsin

Cancer

Discovery Pre-
clinical
Phase 1 Phase 2 Phase 3

PeproStat

Haemostasis

Discovery Pre-
clinical
Phase 1 Phase 2 Phase 3

ReadyFlow

Haemostasis

Discovery Pre-
clinical
Phase 1 Phase 2 Phase 3
IMD

BR4002

Alzheimer’s disease

Discovery Pre-
clinical
Phase 1 Phase 2 Phase 3

BR9003

Smoking cessation treatment

Discovery Pre-
clinical
Phase 1 Phase 2 Phase 3

BR3003

Diabetes

Discovery Pre-
clinical
Phase 1 Phase 2 Phase 3
TOP